Overview

humanized antibody


Related Overviews

 

'humanized antibody' can also refer to...

humanized antibody

humanized antibody

Tabhu: tools for antibody humanization

Humanized-monoclonal antibody against heterologous Leptospira infection

Antibody structure prediction and development of humanization strategies

Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies

Computationally driven antibody engineering enables simultaneous humanization and thermostabilization

Extracting human antibody sequences from public databases for antibody humanization: high frequency of species assignment errors

Humanization of the anti-CEA T84.66 antibody based on crystal structure data

A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing

Humanization of an antibody against human protein C and calcium-dependence involving framework residues.

Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528

Humanization strategies for an anti-idiotypic antibody mimicking HIV-1 gp41

Rat-Specific Decreases in Platelet Count Caused by a Humanized Monoclonal Antibody Against Sclerostin

Opportunistic Infections in 547 Organ Transplant Recipients Receiving Alemtuzumab, a Humanized Monoclonal CD-52 Antibody

Antibodies to human ZP3 induce reversible contraception in transgenic mice with `humanized' zonae pellucidae

Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab

A Case with HER2-overexpressing Breast Cancer Completely Responded to Humanized anti-HER2 Monoclonal Antibody

Effects of humanization by variable domain resurfacing on the antiviral activity of a single-chain antibody against respiratory syncytial virus

 

More Like This

Show all results sharing these subjects:

  • Medicine and Health
  • Chemistry

GO

Show Summary Details

Quick Reference

In general, any nonhuman antibody that has been engineered to have human immunoglobulin domains substituted for all regions except the antigen-binding site. In practice, usually a modified mouse monoclonal antibody directed against a therapeutically important target (e.g. infliximab directed against TNFα). The objective is to make the antibody minimally antigenic so that repeated treatment is possible.

Subjects: Medicine and Health — Chemistry.


Reference entries

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.